No Data
No Data
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting
Buy Rating on PMV Pharmaceuticals: Strategic Partnerships and Promising Clinical Pipeline Underpin Positive Outlook
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective P53 Y220C Reactivator
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma")) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test,
Analysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (PMVP) and Phathom Pharmaceuticals (PHAT)
PMV Pharmaceuticals Initiated at Buy by Craig-Hallum
PMV Pharmaceuticals Initiated at Buy by Craig-Hallum
Express News | Craig-Hallum Initiates Coverage On PMV Pharma With Buy Rating, Announces Price Target of $6